High Content Screening Market Poised for Meteoric Rise, Projected to Reach US$ 3 Billion by 2033 | Future Market Indisghts,Inc fmiblog.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fmiblog.com Daily Mail and Mail on Sunday newspapers.
In this poster, Particle Works presents its work on high-throughput screening of formulations and process conditions for lipid nanoparticles (LNPs). The company has developed the Automated Library Synthesis (ALiS) system, which combines automation, precision, and reusable microfluidic chips to enable rapid preparation and processing of LNP formulations. The system demonstrates excellent consistency in LNP synthesis and recovery from poor formulations through effective cleaning between samples. B
Do particles hold the power to pave the way for new drugs? In this interview, we speak to Ben Knappett, head of science and applications at Particle Works to find out more!
The COVID-19 pandemic brought lipid nanoparticles (LNPs) to prominence, with multiple pharmaceutical manufacturers – including Moderna and Pfizer-BioNTech – rapidly developing mRNA-LNP vaccines that were administered globally. The success of these vaccines has firmly established the potential of this technology to help treat a broad scope of diseases and illnesses, especially using gene therapy approaches, where LNPs are already demonstrating promise as non-viral delivery vectors. How